具有胺催化涂层的氧化释放导管可提高抗炎性能
Qingqing Fan1,2, Shu Geng1, Tanveer A Tabish3
1School of Chemical Engineering and Australian Centre for Nanomedicine (ACN), The University of New South Wales, Sydney, NSW, 2052, Australia.
Advanced healthcare materials
|August 29, 2025
概括
这项研究引入了一种用于导管的新型纳米涂层,该涂层释放氧化 (NO),增强血管功能并减少炎症. 酸和胺涂层可以持续释放NO,并提高细胞活力.
科学领域:
- 生物材料科学
- 纳米技术
- 医疗设备工程
背景情况:
- 氧化 (NO) 对血管扩张,细菌抑制和炎症控制至关重要.
- 目前的NO释放导管在持续释放和制造复杂性方面存在局限性.
研究的目的:
- 开发和描述一种用于催化生成氧化的新型纳米涂层.
- 评估NO释放导管在支持血管功能和减少炎症方面的有效性.
主要方法:
- 开发了一种使用酸 (TA) 和胺 (SeCA) 的纳米涂层.
- 分析了表面特征和NO生成动力学.
- 在体外研究中评估了细胞活力 (HCASMC) 和炎症反应 (巨细胞).
主要成果:
- 在1:4的TA:SeCA摩尔比率下实现了最佳的NO生成.
- 涂层导管在72小时内保持了高达96%的HCASMC活力,并增加了内源NO的产生.
- 在至少3天的时间内观察到7×10−10 mol cm−2 min−1的持续NO释放.
- 在巨细胞中减少了促炎细胞因子 (TNF-α,IL-6).
结论:
- TA/SeCA纳米涂层提供了一种强大而简单的方法,用于从导管中输送NO.
- 涂层的导管显示出增强血管功能和减轻炎症的潜力.
相关概念视频
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Antihypertensive Drugs: Vasodilators
642
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
642
Antianginal Drugs: Nitrates and β-Blockers
749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29


